BD transactions are booming, innovative drugs are entering a period of intensive data-driven catalysts, and the Hong Kong-listed innovative drug ETF Bosera(520690) has risen over 14% in the past week.

Since 2026, China’s innovative drug BD deal values have grown beyond expectations, further boosting the industry’s global competitiveness; the domestic market has ramped up rapidly. From the 2025 annual reports, it can be seen that leading innovative drug companies have seen fast growth in innovative drug revenue driven by new products, and biotech pharmaceuticals have been gradually entering a profitability inflection point; with multiple international academic conferences coming up soon, many innovative drug pipelines have entered a dense period of data catalysts.

CITIC Securities noted that in March 2026, innovative drugs rebounded strongly, mainly benefiting from the normalization of BD transactions, the continued optimization of reporting statement structure through ongoing expansion of commercialized products, and strengthened expectations for key data readouts at AACR 2026 and ASCO 2026. The logic of “going out to sea from following to leading” has been further reinforced. With the Hang Seng Index of Biotech and Pharmaceuticals in Hong Kong having adjusted sufficiently and formed technical support, against the backdrop of a pullback in AI technology stocks, innovative drugs have become a “safe-haven” direction within growth stocks that has a margin of safety.

As of 10:22 on April 3, 2026, the Bosera Hang Seng Hong Kong Innovative Drug ETF (520690) in Hong Kong fell 0.34%, with the latest quote at 0.87 yuan. Looking over a longer period, as of April 2, 2026, the Bosera Hang Seng Hong Kong Innovative Drug ETF in Hong Kong has accumulated a gain of 14.30% over the past 1 week.

In terms of liquidity, the Bosera Hang Seng Hong Kong Innovative Drug ETF in Hong Kong had an intraday turnover rate of 11.84%, with trading volume of 63.04 million yuan, and trading activity in the market has been active. Looking over a longer period, as of April 2, the ETF’s average daily turnover over the past 1 week has been 329 million yuan.

The Bosera Hang Seng Hong Kong Innovative Drug ETF in Hong Kong closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index. The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index is designed to reflect the performance of Hong Kong-listed companies whose businesses are related to innovative drug research, development, and production and that can be bought and sold via Hong Kong Stock Connect.

Data shows that as of April 2, 2026, the top ten constituent stocks by weight in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) are Kangfang Biotech, Innovent Biologics, CSPC Pharmaceutical Group, BeiGene, China Biopharmaceutical, Hansoh Pharmaceutical, Sinheng Pharmaceutical, Kura Oncology (or “Kelun-Betai”?), Innovent? (Note: see original list below), and the top ten by weight together account for 69.65%.

Related products: Bosera Hang Seng Hong Kong Innovative Drug ETF (520690); Bosera Hang Seng Medical ETF (513060), off-exchange connection (Bosera Hang Seng Medical Healthcare ETF Initiation Connect (QDII) A: 014424; Bosera Hang Seng Medical Healthcare ETF Initiation Connect (QDII) C: 014425).

(The individual stocks mentioned in the article are for illustrative purposes only and do not constitute actual investment advice. Funds involve risk; invest cautiously.)

The above products’ risk level is: medium-high (this is the manager’s rating; the specific sales risk rating will be based on ratings by each distributor)

Risk warning: Funds are not financial instruments with fixed-income expectations such as bank savings and bonds. Different types of funds have different risk-return profiles. Investors may both share the gains generated from fund investments and may bear losses arising from fund investments. Past performance of a fund does not indicate its future performance. Investors should understand a fund’s risk-return profile, make a prudent decision in light of their own investment objectives, time horizon, investment experience, and risk tolerance, and bear the risks themselves. They should not rely on sales activities or non-compliant promotional materials that do not meet the requirements of laws and regulations.